Skip to main content
An official website of the United States government

Gastrointestinal Steering Committee

The NCI Gastrointestinal Steering Committee (GISC) was established in January 2006. At monthly meetings, the GISC addresses the design, prioritization, and evaluation of concepts for phase 2 and phase 3 clinical trials in adult gastrointestinal cancers. View the GISC member roster as of May 30, 2024.

Strategic Priorities

  • The GISC Strategic Priorities were formulated with the goal that the majority of submitted concepts would align with these established priorities. They address areas of unmet clinical need, important unanswered clinical questions, and potential new approaches to disease treatment.

Task Forces

  • The following task forces have been established to discuss and refine concepts and facilitate the sharing of ideas and the development of strategic plans among a broad range of clinical investigators, basic and translational scientists, community oncologists, biostatisticians, and patient advocates within a disease subtype (View the GISC Task Force member rosters as of May 30, 2024):
    • Colon Task Force
    • Esophagogastric Task Force
    • Hepatobiliary Task Force
    • Neuroendocrine Tumors (NET) Task Force
    • Pancreas Task Force
    • Rectal-Anal Task Force
  • The Colon and Rectal-Anal task forces met in June 2018 to develop guidelines for research in the use of circulating tumor DNA in the care and management of colorectal cancer. Read the consensus recommendations.
  • The  Rectal-Anal task force held a virtual retreat in March  2021 to develop consensus on the design of future clinical trials for the optimal management of rectal cancer. Read the consensus recommendations.

Clinical Trials Planning Meetings (CTPMs)

CTPMs are held periodically to focus on specific clinical trial-related topics. The following are important, recent GISC CTPMs:

  • Neuroendocrine Tumor PRRT CTPM 
    The NCI Neuroendocrine Tumor Task Force held a CTPM in March 2021 to identify clinical trial strategies to help define the treatment of patients with neuroendocrine tumors in the era of Peptide Receptor Radionuclide Therapy (PRRT). Read the executive summary and full publication in JNCI.
  • Gastroesophageal Carcinoma Immuno-Oncology CTPM 
    The NCI Esophagogastric Task Force held a CTPM in May 2018 to develop strategies for the incorporation of immuno-oncology therapeutic approaches for gastric and esophageal cancer and to identify clinical trial designs to address this unmet need. Read the executive summary.


For more information, contact NCI CCCT Program Director, Wolf Lindwasser, Ph.D. at